New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors

References

• Henderson IC, Canellos GP. Cancer of the breast: The past decade. N. Engl. J. Med.302, 17–30 (1990).
   Google Scholar
• Sasano H, Okamoto M, Mason JI et al. Immunolocalization of aromatase, 17 α-hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary. J. Reprod. Fertil.85, 163–169 (1989).
   PubMedGoogle Scholar
• Sasano H. Functional pathology of human ovarian steroidogenesis: normal cycling ovary and steroid-producing neoplasms. Endocr. Pathol.5, 81–89 (1994).
   Google Scholar
• Miller WR. Aromatase activity in breast tissue. J. Steroid Biochem. Mol. Biol.39, 783–790 (1991).
   PubMed Web of Science ®Google Scholar
• Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by cultured human fibroblasts. J. Clin. Endocrinol. Metab.43, 785–795 (1976).
   PubMed Web of Science ®Google Scholar
• Longcope C, Pratt JH, Schneider SN, Fineberg SE. Aromatization of androgens by muscle and adipose tissue in vivo. J. Clin. Endocrinol. Metab.46, 146–152 (1978).
   PubMed Web of Science ®Google Scholar
• Sasano H, Uzuki M, Sawai T et al. Aromatase in human bone tissue. J. Bone Miner. Res.12, 1416–1423 (1997).
   PubMed Web of Science ®Google Scholar
• Dao TL, Hayes C, Libby PR. Steroid sulfatase activities in human breast tumors. Proc. Soc. Exp. Biol. Med.146, 381–384 (1974).
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Gelly C, Lecerf F. Estrogen sulfates: biological and ultrastructuralresponses and metabolism in MCF-7 human breast cancer cells. Breast Cancer Res. Treat.8, 233–240 (1986).
   PubMedGoogle Scholar
• Aksoy IA, Wood TC, Weinshilboum R. Human liver estrogen sulfotransferase: identification by cDNA cloning and expression. Biochem. Biophys. Res. Commun.200, 1621–1629 (1994).
   PubMed Web of Science ®Google Scholar
• Falany CN, Krasnykh V, Falany JL. Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J. Steroid Biochem. Mol. Biol.52, 529–539 (1995).
   PubMed Web of Science ®Google Scholar
• Dooley TP, Haldeman-Cahill R, Joiner J, Wilborn TW. Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem. Biophys. Res. Commun.277, 236–245 (2000).
   PubMed Web of Science ®Google Scholar
• Peltoketo H, Isomaa V, Maentausta O, Vihko R. Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett.239, 73–77 (1998).
   Google Scholar
• Poutanen M, Isomaa V, Lehto VP, Vihko R. Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int. J. Cancer50, 386–390 (1992).
   PubMed Web of Science ®Google Scholar
• Poutanen M, Isomaa V, Peltoketo H, Vihko R. Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J. Steroid Biochem. Mol. Biol.55, 525–532 (1995).
   PubMed Web of Science ®Google Scholar
• Lipworth L, Adami HO, Trichopoulos D, Carlstrom K, Mantzoros C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology7, 96–100 (1996).
   PubMed Web of Science ®Google Scholar
• Dorgan JF, Stanczyk FZ, Longcope C et al. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 β, 17 β-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev.6, 177–181 (1997).
   PubMedGoogle Scholar
• Berrino F, Muti P, Micheli A et al. Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl Cancer Inst.88, 291–296 (1996).
   PubMed Web of Science ®Google Scholar
• James VHT, Reed MJ, Folkerd EJ. Studies of oestrogen metabolism in postmenopausal women with cancer. J. Steroid Biochem.15, 235–246 (1981).
   PubMedGoogle Scholar
• Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res.52, 1–4 (1992).
   PubMed Web of Science ®Google Scholar
• Miller WR, Hawkins RA, Forrest APM. Significance of aromatase activity in human breast cancer. Cancer Res.42, 3365–3368 (1982).
   Google Scholar
• Perel E, Wilkins D, Killinger DW. The conversion of androstenedione to estrone, estradiol and testosterone in breast tissue. J. Steroid Biochem.13, 89–94 (1980).
   PubMedGoogle Scholar
• Yue W, Wang J-P, Hamilton CJ, Demers LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res.58, 927–932 (1998).
   PubMed Web of Science ®Google Scholar
• Labrie F, Belanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. NY Acad. Sci.774, 16–28 (1995).
   PubMed Web of Science ®Google Scholar
• Sasano H. Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev.19, 593–607 (1998).
   PubMed Web of Science ®Google Scholar
• Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev.26, 331–345 (2005).
   PubMed Web of Science ®Google Scholar
• Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu. Rev. Med.56, 103–116 (2005).
   PubMed Web of Science ®Google Scholar
• Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews YL. Prognostic value of breast cancer aromatase. Cancer70, 1951–1955 (1992).
   PubMedGoogle Scholar
• Sasano H, Anderson TJ, Silverberg SG et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry – a correlation with biochemical activities in 46 cases of breast cancer. J. Steroid Biochem. Mol. Biol.95, 35–39 (2005).
   PubMed Web of Science ®Google Scholar
• Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab.81, 3843–3849 (1996).
   PubMed Web of Science ®Google Scholar
• Clyne CD, Speed CJ, Zhou J, Simpson ER. Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J. Biol. Chem.277, 20591–20597 (2002).
   PubMedGoogle Scholar
• Zhou J, Suzuki T, Kovacic A et al. Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res.65, 657–663 (2005).
   Google Scholar
• Reed MJ, Purohit A. Aromatase regulation and breast cancer. Clin. Endocrinol.54, 563–571 (2001).
   PubMed Web of Science ®Google Scholar
• Luu-The V, Labrie C, Zhao HF et al. Characterization of cDNAs for human estradiol 17b-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5´-termini in human placenta. Mol. Endocrinol.3, 1301–1309 (1989).
   PubMedGoogle Scholar
• Takeyama J, Sasano H, Suzuki T, Iinuma K, Nagura H. Andersson S. 17β-hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development. J. Clin. Endocrinol. Metab.83, 3710–3715 (1998).
   Google Scholar
• Miettinen M, Mustonen M, Poutanen M et al. P17β-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res. Treat.57, 175–182 (1999).
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer94, 685–689 (2001).
   PubMed Web of Science ®Google Scholar
• Pasqualini JR. The selective estrogen enzyme modulators in breast cancer, a review. Biochim. Biophys. Acta1654, 123–143 (2004).
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Ahnstrom M, Kirschner K et al. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene22, 34–40 (2003).
   Google Scholar
• Ariga N, Moriya T, Suzuki T et al. 17 β-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Res.20, 1101–1108 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17β-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br. J. Cancer82, 518–523 (2000).
   PubMedGoogle Scholar
• Allan GM, Lawrence HR, Cornet J et al. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J. Med. Chem.49, 1325–1345 (2006).
   PubMed Web of Science ®Google Scholar
• Fischer DS, Allan GM, Bubert C et al. E-ring modified steroids as novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J. Med. Chem.485749–485770 (2005).
   Google Scholar
• Tremblay MR, Boivin RP, Luu-The V, Poirier D. Inhibitors of type 1 17β-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol. J. Enzyme Inhib. Med. Chem.20, 153–163 (2005).
   PubMed Web of Science ®Google Scholar
• Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr. Rev.26, 171–202 (2005).
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol.93, 221–236 (2005).
   PubMed Web of Science ®Google Scholar
• Utsumi T, Yoshimura N, Takeuchi S et al. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res.59, 377–381 (1999).
   PubMed Web of Science ®Google Scholar
• Saeki T, Takashima S, Sasaki H, Hanai N, Salomon DS. Localization of estrone sulfatase in human breast carcinomas. Breast Cancer6, 331–337 (1999).
   Google Scholar
• Suzuki T, Nakata T, Miki Y et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res.63, 2762–2770 (2003).
   PubMed Web of Science ®Google Scholar
• Santner SJ, Feil PD, Santen RJ. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab.59, 29–33 (1984).
   PubMed Web of Science ®Google Scholar
• Evans TR, Rowlands MG, Law M, Coombes RC. Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br. J. Cancer69, 555–561 (1994).
   PubMedGoogle Scholar
• Nussbaumer P, Billich A. Steroid sulfatase inhibitors: their potential in the therapy of breast cancer. Curr. Med. Chem. Anticancer Agents5, 507–528 (2005).
   PubMedGoogle Scholar
• Stanway SJ, Purohit A, Woo LW et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res.12, 1585–1592 (2006).
   PubMed Web of Science ®Google Scholar
• Raobaikady B, Day JM, Purohit A, Potter BV, Reed MJ. The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites J. Steroid Biochem. Mol. Biol.94229–94237 (2005).
   Google Scholar